---
title: "Cogent Biosciences Submits New Drug Application for Bezuclastinib in Nonadvanced Systemic Mastocytosis"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275462672.md"
datetime: "2026-02-10T13:02:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275462672.md)
  - [en](https://longbridge.com/en/news/275462672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275462672.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275462672.md) | [English](https://longbridge.com/en/news/275462672.md)


# Cogent Biosciences Submits New Drug Application for Bezuclastinib in Nonadvanced Systemic Mastocytosis

Cogent Biosciences Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for bezuclastinib in the treatment of nonadvanced systemic mastocytosis (NonAdvSM). The submission, announced in December 2025, is based on positive clinical data from the SUMMIT pivotal trial and follows the Breakthrough Therapy Designation previously granted for bezuclastinib in patients with SSM and NonAdvSM who have received prior avapritinib. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Cogent Biosciences (COGT.US)](https://longbridge.com/zh-HK/quote/COGT.US.md)

## 相關資訊與研究

- [Cogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib](https://longbridge.com/zh-HK/news/281388189.md)
- [Cogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026](https://longbridge.com/zh-HK/news/281483548.md)
- [Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches](https://longbridge.com/zh-HK/news/279128708.md)
- [Cardinal Health Boosts Actinium-225 Production Capacity to Meet Demand for Novel Cancer Therapies](https://longbridge.com/zh-HK/news/281360890.md)
- [Global Net Lease Declares Q2 2026 Common Dividend](https://longbridge.com/zh-HK/news/281364010.md)